321 HARRISON AVENUE, BOSTON, MA
Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Earnings Release
2026 Annual Meeting Results; Three Directors Elected at Monte Rosa Therapeutics
Announces First Quarter 2026 Financial Results and Business Updates
Annual Report to Security Holders
Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
SVP Edmund Dunn Retirement; Matthew Bowen Named Successor
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence